R&D | Cutting-edge science and innovative research

R&D

Clinician contemplating a tablet and protocols for CT design

Navigating the new ICH E6 (R3): Key changes for sponsors

These new regulations for running clinical trials in the UK will be a legal requirement from 28th April 2026.

News

Novo Nordisk's CagriSema tops Ozempic in diabetes trial

Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.

News

GSK departs Wave's AATD programme

Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active.

R&D

Sponsored

Organoid neurotoxicity testing gains momentum

Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.

News

Mixed data mars Sanofi's venglustat programme

Sanofi has reported positive phase 3 results with venglustat in Gauder disease, but the drug missed the mark in a Fabry disease trial.

News

GSK departs Wave's AATD programme

Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active.

R&D

Sponsored

Organoid neurotoxicity testing gains momentum

Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.

News

Mixed data mars Sanofi's venglustat programme

Sanofi has reported positive phase 3 results with venglustat in Gauder disease, but the drug missed the mark in a Fabry disease trial.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Novo Nordisk's CagriSema tops Ozempic in diabetes trial

Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.

News

GSK departs Wave's AATD programme

Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Navigating the new ICH E6 (R3): Key changes for sponsors

These new regulations for running clinical trials in the UK will be a legal requirement from 28th April 2026.

R&D

Sponsored

Organoid neurotoxicity testing gains momentum

Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

Deep Dive

R&D

R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research.

R&D

Breaking through financial barriers to clinical trials: How ...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 239, Dr Jorg Schuttrumpf

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

Video

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

R&D

Interview at JPM26 with Adrian Woolfson and Kaihang Wang from Genyro

DNA as a programmable language, with Adrian Woolfson and Kai...

A new technology just announced this weekend in a paper in Nature could have a radical impact on how gene assembly is carried out.

R&D

The secrets of the secretome, with Hans Keirstead

Immunis CEO Hans Keirstead explains why his company thinks the immune system is key to tackling healthspan and longevity.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D

Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

R&D

Life Sciences Industry Report - Rare Disease Space

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

Event

Partner Content

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam

R&D

Partner Content

5th mRNA-Based Therapeutics Summit Europe

The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines

R&D

Partner Content

10th Tumor Models Summit San Francisco

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity

Partner Content

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam

R&D

Partner Content

5th mRNA-Based Therapeutics Summit Europe

The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines

R&D

Partner Content

10th Tumor Models Summit San Francisco

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity

Navigating the new ICH E6 (R3): Key changes for sponsors

Novo Nordisk's CagriSema tops Ozempic in diabetes trial

GSK departs Wave's AATD programme

Organoid neurotoxicity testing gains momentum

Mixed data mars Sanofi's venglustat programme

GSK departs Wave's AATD programme

Organoid neurotoxicity testing gains momentum

Mixed data mars Sanofi's venglustat programme

Synthetic control arms in clinical trials: Making it happen

How synthetic control arms are changing clinical trials

Novo Nordisk's CagriSema tops Ozempic in diabetes trial

GSK departs Wave's AATD programme

Touring Chiesi's vision for the future at the new Biotech Ce...

Vir awarded $1 billion multi-year BARDA influenza contract

Navigating the new ICH E6 (R3): Key changes for sponsors

Organoid neurotoxicity testing gains momentum

Allogeneic cell therapy isn’t dead, with Brian Culley

Research and Development

Deep Dive: Research and Development 2025

Breaking through financial barriers to clinical trials: How ...

Exploring the future: Opportunities and challenges in cell a...

Beyond clinical: Boosting recruitment and retention with SDO...

The evolution of clinical research: Embracing new delivery m...

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

On genomics, NGS, and doing much more good than bad, with Ma...

Harnessing the cell's own degradation machinery, with Benedi...

Allogeneic cell therapy isn’t dead, with Brian Culley

DNA as a programmable language, with Adrian Woolfson and Kai...

The secrets of the secretome, with Hans Keirstead

A New Framework to Engineer Breakthrough Value for Medicines

Life Sciences Industry Report - Biologics and Generics

Life Sciences Industry Report - Rare Disease Space

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

5th mRNA-Based Therapeutics Summit Europe

10th Tumor Models Summit San Francisco

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

5th mRNA-Based Therapeutics Summit Europe

10th Tumor Models Summit San Francisco

A cancer treatment modality that prioritises QoL, with Ben Z...

How to meet your physicians where they are online

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Editor's Picks